# Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium

> **NCT06073184** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 71 (estimated)

## Conditions studied

- Endometrial Cancer
- Atypical Hyperplasia

## Interventions

- **DRUG:** Mounjaro
- **DRUG:** Mirena

## Key facts

- **NCT ID:** NCT06073184
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2027-02
- **Final completion:** 2032-02
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06073184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06073184, "Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06073184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*